DABIGATRAN ETEXILATE ZENTIVA K.S. 75 mg, hard capsule 30 capsules
Active ingredients: DABIGATRAN ÉTEXILATE, MÉSILATE DE DABIGATRAN ÉTEXILATE
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule30 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DABIGATRAN ETEXILATE ZENTIVA K.S. 75 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 30 plaquettes prédécoupées unitaires aluminium OPA : polyamide orienté PVC de 1 gélule
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Oct 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68185986CIP73028933CIP133400930289334Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DABIGATRAN ÉTEXILATEgélule | 75 mg · une gélule | FT |
| MÉSILATE DE DABIGATRAN ÉTEXILATEgélule | 86,48 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
Group of similar medicines: DABIGATRAN ETEXILATE (MESILATE DE) équivalant à DABIGATRAN ETEXILATE 75 mg - PRADAXA 75 mg, gélule